Form 4: Myriad Genetics Director, Daniel Skovronsky, Reports Acquisition of Restricted Stock Units

Director Daniel Skovronsky reports acquisition of Myriad Genetics restricted stock units.

Summary

• On June 6, 2024, Daniel Skovronsky, a director of Myriad Genetics Inc., reported the acquisition of 15,695 shares of common stock in the form of restricted stock units.
• These restricted stock units were granted pursuant to the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each unit represents a contingent right to receive one share of common stock.
• The units vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.
• Following the transaction, Skovronsky beneficially owns 86,010 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.
• The vesting schedule aligns the director's interests with those of the shareholders.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, aligning the director's interests with the company's performance.

Industry Context

Acquisition of stock by company directors is a common practice to align management's interests with shareholders.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder confidence.

Key Dates